SBIR/STTR Research Award
Novel Vaccine Technologies and Strategies to Promote Sustained Vaccine Efficiency
Award amount
$450,000Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROFECTUS BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
The overarching objective of this proposal is the identification of novel vaccination regimen sleading to improved malaria vaccine efficacyThe medical need for such a vaccine remains compellingTo accomplish this goaltwo attenuatedheterologous viral vaccine vectorsrecombinant vesicular stomatitis virusrVSVand recombinant Isfahan virusrISFVabundantly expressing Plasmodium falciparum circumsporozoite surface proteinCSPwill be generated and characterized in vitroSpecific AimVector safety will be confirmed in a mouse intracranial neurovirulence modelSpecific Aimand CSP specific immune responses will be assessed in mice to determine an optimal heterologous prime boost vaccination regimenSpecific AimBoth vectors are attenuated and replication competentthey are serologically distinct and phylogenetically divergentreducing potential immunological cross reactivity between themWe expect that both vectors used in heterologous prime boost vaccination regimenswill elicit very robust and durable CSP specific cellular and humoral immune responsesBecause current malaria vaccines have demonstrated only modest protection from diseasenew and improved malaria vaccines and vaccine regimens are urgently needed to protect the millions of people at risk from this widespread and deadly disease
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients